» Articles » PMID: 33844988

Fecal Microbiota Transplantation for Recurrent Clostridioides Difficile Infection Associates With Functional Alterations in Circulating MicroRNAs

Abstract

Background And Aims: The molecular mechanisms underlying successful fecal microbiota transplantation (FMT) for recurrent Clostridioides difficile infection (rCDI) remain poorly understood. The primary objective of this study was to characterize alterations in microRNAs (miRs) following FMT for rCDI.

Methods: Sera from 2 prospective multicenter randomized controlled trials were analyzed for miRNA levels with the use of the Nanostring nCounter platform and quantitative reverse-transcription (RT) polymerase chain reaction (PCR). In addition, rCDI-FMT and toxin-treated animals and ex vivo human colonoids were used to compare intestinal tissue and circulating miRs. miR inflammatory gene targets in colonic epithelial and peripheral blood mononuclear cells were evaluated by quantitative PCR (qPCR) and 3'UTR reporter assays. Colonic epithelial cells were used for mechanistic, cytoskeleton, cell growth, and apoptosis studies.

Results: miRNA profiling revealed up-regulation of 64 circulating miRs 4 and 12 weeks after FMT compared with screening, of which the top 6 were validated in the discovery cohort by means of RT-qPCR. In a murine model of relapsing-CDI, RT-qPCR analyses of sera and cecal RNA extracts demonstrated suppression of these miRs, an effect reversed by FMT. In mouse colon and human colonoids, C difficile toxin B (TcdB) mediated the suppressive effects of CDI on miRs. CDI dysregulated DROSHA, an effect reversed by FMT. Correlation analyses, qPCR ,and 3'UTR reporter assays revealed that miR-23a, miR-150, miR-26b, and miR-28 target directly the 3'UTRs of IL12B, IL18, FGF21, and TNFRSF9, respectively. miR-23a and miR-150 demonstrated cytoprotective effects against TcdB.

Conclusions: These results provide novel and provocative evidence that modulation of the gut microbiome via FMT induces alterations in circulating and intestinal tissue miRs. These findings contribute to a greater understanding of the molecular mechanisms underlying FMT and identify new potential targets for therapeutic intervention in rCDI.

Citing Articles

Systematic review of bidirectional interaction between gut microbiome, miRNAs, and human pathologies.

Drago L, De La Motte L, Deflorio L, Sansico D, Salvatici M, Micaglio E Front Microbiol. 2025; 16:1540943.

PMID: 39973938 PMC: 11835932. DOI: 10.3389/fmicb.2025.1540943.


Research progress on the interaction between intestinal flora and microRNA in pelvic inflammatory diseases.

Dong S, Du Y, Wang H, Yuan W, Ai W, Liu L Noncoding RNA Res. 2025; 11:303-312.

PMID: 39931541 PMC: 11808595. DOI: 10.1016/j.ncrna.2025.01.007.


Gut Microbiota Secondary Metabolites: Key Roles in GI Tract Cancers and Infectious Diseases.

Anwer E, Ajagbe M, Sherif M, Musaibah A, Mahmoud S, ElBanbi A Biomedicines. 2025; 13(1).

PMID: 39857684 PMC: 11762448. DOI: 10.3390/biomedicines13010100.


Unraveling the Microbiome-Human Body Axis: A Comprehensive Examination of Therapeutic Strategies, Interactions and Implications.

Olteanu G, Ciuca-Pana M, Busnatu S, Lupuliasa D, Neacsu S, Mititelu M Int J Mol Sci. 2024; 25(10).

PMID: 38791599 PMC: 11122276. DOI: 10.3390/ijms25105561.


Fecal microbiota transplantation: current challenges and future landscapes.

Yadegar A, Bar-Yoseph H, Monaghan T, Pakpour S, Severino A, Kuijper E Clin Microbiol Rev. 2024; 37(2):e0006022.

PMID: 38717124 PMC: 11325845. DOI: 10.1128/cmr.00060-22.


References
1.
Kao D, Roach B, Silva M, Beck P, Rioux K, Kaplan G . Effect of Oral Capsule- vs Colonoscopy-Delivered Fecal Microbiota Transplantation on Recurrent Clostridium difficile Infection: A Randomized Clinical Trial. JAMA. 2017; 318(20):1985-1993. PMC: 5820695. DOI: 10.1001/jama.2017.17077. View

2.
Monaghan T, Mullish B, Patterson J, Wong G, Marchesi J, Xu H . Effective fecal microbiota transplantation for recurrent Clostridioides difficile infection in humans is associated with increased signalling in the bile acid-farnesoid X receptor-fibroblast growth factor pathway. Gut Microbes. 2018; 10(2):142-148. PMC: 6546339. DOI: 10.1080/19490976.2018.1506667. View

3.
Nowarski R, Jackson R, Gagliani N, de Zoete M, Palm N, Bailis W . Epithelial IL-18 Equilibrium Controls Barrier Function in Colitis. Cell. 2015; 163(6):1444-56. PMC: 4943028. DOI: 10.1016/j.cell.2015.10.072. View

4.
Chen G, Feng Y, Li X, Jiang Z, Bei B, Zhang L . Post-transcriptional Gene Regulation in Colitis Associated Cancer. Front Genet. 2019; 10:585. PMC: 6593052. DOI: 10.3389/fgene.2019.00585. View

5.
Chandrasekaran R, Lacy D . The role of toxins in Clostridium difficile infection. FEMS Microbiol Rev. 2017; 41(6):723-750. PMC: 5812492. DOI: 10.1093/femsre/fux048. View